Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877959 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL989886 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL2631691 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL2631626 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL11886494 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL18597912 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL11886502 | 1.00 | BACE1 (0.39) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL21764457 | 0.89 | BACE1 (0.33) | BACE1KDM1ARCOR1 | |
| SCHEMBL11886469 | 0.87 | BACE1 (0.36) | BACE1BACE2KCNN4KDM1ARCOR1 | |
| SCHEMBL8034853 | 0.86 | BACE1 (0.35) | BACE1BACE2KCNN4KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456774-B1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885KCNN4 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.